Multiplex assay for genetic testing of thrombophilia: a method for routine clinical care

There is an increasing demand for genetic testing of patients with hypercoagulability. We have developed a multiplex‐polymerase chain reaction (PCR) technique that incorporates the state‐of‐the art of genetic testing for thrombosis mutations (Factor V Leiden [FVL] and G20210A F2 and C46T F12). The sequences are detected by enzyme‐linked immunosorbent assay (ELISA)‐resolved colorimeter after hybridization with an amplification product labeled with digoxygenin. To evaluate the reliability of this method, we analyzed 122 deoxyribonucleic acid (DNA) samples of known genotypes for these three mutations. Six subjects initially assigned as heterozygous for FVL and two subjects assigned as normal for the G20210A F2 mutation showed discrepancies between the current techniques and our newly‐developed ELISA‐based technique. When these samples were sequenced the concordance using our method was 100%. Thus, initially they were assigned incorrectly based on the available methodologies. It is noteworthy that our method is adaptable to an Automated ELISA Analyzer that allows for routine processing of both small and large numbers of DNA samples. We present a robust, rapid, reproducible, cost‐effective, and simple multiplex PCR ELISA method to simultaneously detect carriers of thrombotic genetic risk factors. Testing for thrombophilia should contribute to better diagnosis, prevention, and treatment strategies, providing valuable information to assess the risk of recurrence in the proband, and in family members who are asymptomatic. J. Clin. Lab. Anal. 21:349–355, 2007. © 2007 Wiley‐Liss, Inc.

[1]  M. Verstraete,et al.  A European view on the North American fifth consensus on antithrombotic therapy. , 2000, Chest.

[2]  J. Fontcuberta,et al.  New approaches and future prospects for evaluating genetic risk of thrombosis. , 2005, Haematologica.

[3]  L. Almasy,et al.  Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. , 2000, American journal of human genetics.

[4]  F. Marín,et al.  Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. , 2005, Haematologica.

[5]  A. Lanthaler,et al.  Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR. , 1999, Haematologica.

[6]  P. Reitsma,et al.  Resistance to Activated Protein C and Factor V Leiden as Risk Factors for Venous Thrombosis , 1995, Thrombosis and Haemostasis.

[7]  B. Dahlbäck,et al.  Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. , 1995, Blood.

[8]  J. Fontcuberta,et al.  Association after linkage analysis indicates that homozygosity for the 46C→T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis , 2004, Thrombosis and Haemostasis.

[9]  L. Drouet,et al.  Multiplex PCR-mediated Site-directed Mutagenesis for One-step Determination of Factor V Leiden and G20210A Transition of the Prothrombin Gene , 1997, Thrombosis and Haemostasis.

[10]  J. Fontcuberta,et al.  Rapid detection of the 46C --> T polymorphism in the factor XII gene, a novel genetic risk factor for thrombosis, by melting peak analysis using fluorescence hybridization probes. , 2003, Genetic testing.

[11]  A. Zivelin,et al.  Thrombophilia as a Multigenic Disorder , 1997, Thrombosis and Haemostasis.

[12]  K. Livak,et al.  A homogeneous, ligase-mediated DNA diagnostic test. , 1998, Genome research.

[13]  J. Fontcuberta,et al.  Homozygosity of the T allele of the 46 C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. , 2004, Haematologica.

[14]  P. Reitsma,et al.  Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. , 1994 .

[15]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[16]  B. Lindblad,et al.  A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.

[17]  J. Wisotzkey,et al.  Simultaneous Polymerase Chain Reaction Restriction Fragment Length Polymorphism Identification of the Factor V Leiden Allele and the Prothrombin 20210A Mutation , 1998, Diagnostic molecular pathology (Print).

[18]  Muin J Khoury,et al.  Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. , 2003, American journal of human genetics.

[19]  V. Armstrong,et al.  Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. , 1999, Clinical chemistry.

[20]  M. Powell,et al.  Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. , 1998, Analytical biochemistry.

[21]  Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. , 1999, Thrombosis research.

[22]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[23]  D. Dawson,et al.  Development of a simple multiplex polymerase chain reaction for the simultaneous detection of factor V Leiden and prothrombin 20210A mutations. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[24]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[25]  J. Martí-Fàbregas,et al.  Homozygosity of the T Allele of the 46 C→T Polymorphism in the F12 Gene Is a Risk Factor for Ischemic Stroke in the Spanish Population , 2004, Stroke.

[26]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[27]  G. Muriel,et al.  An even easier method for one-step detection of both FV Leiden and FII G20210A transition. , 1998, Blood.

[28]  J. Keller,et al.  Venous Thromboembolism and Other Venous Disease in the Tecumseh Community Health Study , 1973, Circulation.

[29]  Fred Russell Kramer,et al.  Spectral Genotyping of Human Alleles , 1998, Science.

[30]  P. Reitsma,et al.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.

[31]  L. Almasy,et al.  A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. , 2002, American journal of human genetics.

[32]  P. Mannucci,et al.  Inherited Thrombophilia: Part 1 , 1996, Thrombosis and Haemostasis.

[33]  J. Fontcuberta,et al.  The Prothrombin 20210A Allele Is the Most Prevalent Genetic Risk Factor for Venous Thromboembolism in the Spanish Population , 1998, Thrombosis and Haemostasis.